< Zurück zu den aktuellen Neuigkeiten & Events

HGF Presents

Patenting Polymorphs at the EPO

September 2025

Video overview:

Novelty and Inventive Step

  • Prior art must necessarily lead to the claimed polymorph to be novelty destroying
  • Watch out for inherent disclosures in prior art—methods may implicitly produce polymorphs even if structural data isn’t provided.
  • Provide experimental evidence if needed to show prior art does not produce the claimed polymorph.
  • Emphasize any advantages or unexpected properties of the polymorph, ideally supported by data, to support an inventive step, in the application.
  • Highlight advantages of the polymorph versus other forms.

Clarity

  • Provide a clear, precise definition of the polymorph.
  • Clearly define the crystalline form using appropriate physicochemical parameters and measurement conditions.

Sufficiency

  • Clearly describe how to prepare the polymorph. If preparation requires seeding crystals, disclose how to prepare the seed in the application.

Aktuelle Neuigkeiten

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Weiterlesen
Event - 14. Oktober 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Veranstaltungsdetails

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Weiterlesen

T 0792/24: Novelty and Inventiveness of Second Medical Use Claims

The EPO Board of Appeal’s decision in T 0792/24 provides helpful guidance on the assessment of novelty and inventive step for European second medical use claims. In light of a …

Weiterlesen

HGF hoch platziert im Legal 500 2026

Die Rangliste des Legal 500 UK 2026 wurde veröffentlicht und HGF wurde erneut in mehreren Regionen und Praxisbereichen platziert. HGF ist weiterhin in der Spitzenklasse des britischen PATMA – Markenzeichen …

Weiterlesen

12 Anwälte von HGF als „Managing IP Rising Stars 2025” ausgezeichnet

Wir sind sehr stolz darauf, bekannt geben zu dürfen, dass 12 unserer Anwälte in den aktuellen „Managing IP Rankings” als „Rising Stars” ausgezeichnet wurden! Diese Auszeichnung würdigt die nächste Generation …

Weiterlesen

IP Ingredients: The companies making – and patenting - alt coffee

How do you like your coffee? Frothy or flat? Milky or black? Oat-milk or soy?  How about coffee which isn’t derived from coffee beans? Coffee is the second most traded …

Weiterlesen
Event - 29. September 2025

HGF ist Bronze-Sponsor der LES Pan-European Conference 2025

Wir sind stolz darauf, Bronze-Sponsor der LES Pan-European Conference 2025 zu sein, die vom 29. bis 30. September 2025 im The Hague Marriott Hotel in den Niederlanden stattfindet. Die diesjährige …

Veranstaltungsdetails